Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study
that will enroll approximately 564 T2DM patients who before screening have inadequately
controlled blood glucose （7.0%≤HbA1c≤10.5% at randomization）despite at least 8 weeks of
metformin monotherapy at stable doses（≥1500 mg/day).